glp-1 egfr cut off Updated evidence on cardiovascular and renal effects of receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology Real-World Evidence for GLP-1 Receptor

The Diabetes Prevention Program demonstrated that intensive lifestyle interventiontargeting 7% weight loss through reduced caloric intake (1200-1800 kcal/day based on initial weight) and 150 minutes weekly of moderate physical activityreduced type 2 diabetes incidence by 58% over three years

GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

But it surely wont be the last, and the competition over the best obesity drug is only likely to heat up in the years to come.

Historically, the role of GIP in obesity treatment was overlooked due to its potential to cause weight gain

doi: 10.1016/j.bbr.2016.10.033 207 BombaMCiavardelliDSilvestriECanzonieroLMLattanzioRChiappiniPet al